Pfizer (1PFE) Stock Forecast & Price Target

10 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

1PFE Analyst Ratings

Moderate Buy

8 Buy

14 Hold

1 Sell

Based on 23 analysts giving stock ratings to

Pfizer

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

1PFE Stock 12 Month Forecast

Average Price Target

€26.52

▲(10.03% Upside)

Based on 23 Wall Street analysts offering 12 month price targets for Pfizer in the last 3 months. The average price target is €26.52 with a high forecast of €32.23 and a low forecast of €22.38. The average price target represents a 10.03% change from the last price of €24.10.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"18":"€18","33":"€33","21.75":"€21.8","25.5":"€25.5","29.25":"€29.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":32.23085904,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€32.23</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26.517420942631578,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€26.52</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22.382541,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€22.38</span>\n  </div></div>","useHTML":true}}],"tickPositions":[18,21.75,25.5,29.25,33],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.225,25.763912233846156,26.302824467692307,26.841736701538462,27.380648935384617,27.919561169230768,28.458473403076923,28.997385636923077,29.536297870769232,30.075210104615383,30.614122338461538,31.15303457230769,31.691946806153844,{"y":32.23085904,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.225,25.324416995587047,25.42383399117409,25.523250986761134,25.62266798234818,25.72208497793522,25.821501973522267,25.920918969109312,26.020335964696358,26.1197529602834,26.219169955870445,26.31858695145749,26.418003947044532,{"y":26.517420942631578,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.225,25.006349307692307,24.787698615384617,24.569047923076923,24.350397230769232,24.131746538461538,23.913095846153848,23.694445153846154,23.475794461538463,23.25714376923077,23.03849307692308,22.819842384615384,22.601191692307694,{"y":22.382541,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21.463,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.89,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.837,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.181,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.7,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.706,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.479,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.034,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.591,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 45, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.608,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.705,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.695,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.225,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€32.23

Average Price Target€26.52

Lowest Price Target€22.38

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Geoff Meacham

Citi

€24.17

Hold

0.30%

Upside

Reiterated

10/13/26

Analysts Offer Insights on Healthcare Companies: Pfizer (NYSE: PFE), Palvella Therapeutics (NASDAQ: PVLA) and Mineralys Therapeutics, Inc. (NASDAQ: MLYS)

Vamil Divan

Guggenheim

€27.75

Buy

15.16%

Upside

Reiterated

10/12/26

Analysts' Top Healthcare Picks: Pfizer (PFE), AbbVie (ABBV)

Mohit Bansal

Wells Fargo

€25.07

Hold

4.02%

Upside

Reiterated

10/12/26

Analysts Conflicted on These Healthcare Names: 4D Molecular Therapeutics (NASDAQ: FDMT), Pfizer (NYSE: PFE) and Incyte (NASDAQ: INCY)

Evan Seigerman

BMO Capital

€31.34

Buy

30.02%

Upside

Reiterated

10/12/26

Analysts Offer Insights on Healthcare Companies: Pfizer (NYSE: PFE), ACADIA Pharmaceuticals (NASDAQ: ACAD) and Insmed (NASDAQ: INSM)

Jason Gerberry

Bank of America Securities

€24.17→€25.96

Hold

7.73%

Upside

Reiterated

10/09/26

Pfizer price target raised to $29 from $27 at BofAPfizer price target raised to $29 from $27 at BofA

Chris Schott

J.P. Morgan

€25.07→€26.86

Hold

11.45%

Upside

Assigned

10/09/26

J.P. Morgan Keeps Their Hold Rating on Pfizer (PFE)

Michael Yee

UBS

€24.17

Hold

0.30%

Upside

Reiterated

10/09/26

Pfizer (PFE) Gets a Hold from UBS

Trung Huynh

RBC Capital

€22.38

Hold

-7.13%

Downside

Reiterated

10/08/26

Analysts Offer Insights on Healthcare Companies: Cogstate Ltd (Other OTC: COGZF) and Pfizer (NYSE: PFE)

Akash Tewari

Jefferies

€31.34→€32.23

Buy

33.74%

Upside

Reiterated

10/08/26

Pfizer (PFE) Receives a Buy from Jefferies

Carter Gould

Cantor Fitzgerald

€24.17→€25.07

Hold

4.02%

Upside

Assigned

10/08/26

Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (NASDAQ: TNGX), Glaukos (NYSE: GKOS) and Pfizer (NYSE: PFE)

Nico Chen

DBS

€31.34

Buy

30.02%

Upside

Reiterated

10/08/26

DBS Keeps Their Buy Rating on Pfizer (PFE)

Terence Flynn

Morgan Stanley

€25.07

Hold

4.02%

Upside

Assigned

10/07/26

Morgan Stanley Issues a Hold Rating on Pfizer (PFE)

Louise Chen

Scotiabank

€26.86→€29.54

Buy

22.59%

Upside

Reiterated

10/07/26

Pfizer price target raised to $33 from $30 at ScotiabankPfizer price target raised to $33 from $30 at Scotiabank

Kerry Holford

Berenberg Bank

€22.38

Hold

-7.13%

Downside

Reiterated

10/07/26

Pfizer (PFE) Receives a Hold from Berenberg Bank

Unknown Analyst

Leerink Partners

Not Ranked

Leerink Partners

―

Hold

―

Reiterated

10/02/26

Pfizer (PFE) Receives a Hold from Leerink Partners

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Geoff Meacham

Citi

€24.17

Hold

0.30%

Upside

Reiterated

10/13/26

Analysts Offer Insights on Healthcare Companies: Pfizer (NYSE: PFE), Palvella Therapeutics (NASDAQ: PVLA) and Mineralys Therapeutics, Inc. (NASDAQ: MLYS)

Vamil Divan

Guggenheim

€27.75

Buy

15.16%

Upside

Reiterated

10/12/26

Analysts' Top Healthcare Picks: Pfizer (PFE), AbbVie (ABBV)

Mohit Bansal

Wells Fargo

€25.07

Hold

4.02%

Upside

Reiterated

10/12/26

Analysts Conflicted on These Healthcare Names: 4D Molecular Therapeutics (NASDAQ: FDMT), Pfizer (NYSE: PFE) and Incyte (NASDAQ: INCY)

Evan Seigerman

BMO Capital

€31.34

Buy

30.02%

Upside

Reiterated

10/12/26

Analysts Offer Insights on Healthcare Companies: Pfizer (NYSE: PFE), ACADIA Pharmaceuticals (NASDAQ: ACAD) and Insmed (NASDAQ: INSM)

Jason Gerberry

Bank of America Securities

€24.17→€25.96

Hold

7.73%

Upside

Reiterated

10/09/26

Pfizer price target raised to $29 from $27 at BofAPfizer price target raised to $29 from $27 at BofA

Chris Schott

J.P. Morgan

€25.07→€26.86

Hold

11.45%

Upside

Assigned

10/09/26

J.P. Morgan Keeps Their Hold Rating on Pfizer (PFE)

Michael Yee

UBS

€24.17

Hold

0.30%

Upside

Reiterated

10/09/26

Pfizer (PFE) Gets a Hold from UBS

Trung Huynh

RBC Capital

€22.38

Hold

-7.13%

Downside

Reiterated

10/08/26

Analysts Offer Insights on Healthcare Companies: Cogstate Ltd (Other OTC: COGZF) and Pfizer (NYSE: PFE)

Akash Tewari

Jefferies

€31.34→€32.23

Buy

33.74%

Upside

Reiterated

10/08/26

Pfizer (PFE) Receives a Buy from Jefferies

Carter Gould

Cantor Fitzgerald

€24.17→€25.07

Hold

4.02%

Upside

Assigned

10/08/26

Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (NASDAQ: TNGX), Glaukos (NYSE: GKOS) and Pfizer (NYSE: PFE)

Nico Chen

DBS

€31.34

Buy

30.02%

Upside

Reiterated

10/08/26

DBS Keeps Their Buy Rating on Pfizer (PFE)

Terence Flynn

Morgan Stanley

€25.07

Hold

4.02%

Upside

Assigned

10/07/26

Morgan Stanley Issues a Hold Rating on Pfizer (PFE)

Louise Chen

Scotiabank

€26.86→€29.54

Buy

22.59%

Upside

Reiterated

10/07/26

Pfizer price target raised to $33 from $30 at ScotiabankPfizer price target raised to $33 from $30 at Scotiabank

Kerry Holford

Berenberg Bank

€22.38

Hold

-7.13%

Downside

Reiterated

10/07/26

Pfizer (PFE) Receives a Hold from Berenberg Bank

Unknown Analyst

Leerink Partners

Not Ranked

Leerink Partners

―

Hold

―

Reiterated

10/02/26

Pfizer (PFE) Receives a Hold from Leerink Partners

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

REPLReplimune Group

OVIDOvid Therapeutics

IMUXImmunic

PTGXProtagonist Therapeutics

ESTAEstablishment Labs Holdings

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Pfizer

3 Months

Vamil DivanGuggenheim

Success Rate

24/33 ratings generated profit

Average Return

+3.85%

Copying Vamil Divan's trades and holding each position for 3 Months would result in 72.73% of your transactions generating a profit, with an average return of +3.85% per trade.

1 Year

Vamil DivanGuggenheim

Success Rate

29/33 ratings generated profit

Average Return

+10.05%

Copying Vamil Divan's trades and holding each position for 1 Year would result in 87.88% of your transactions generating a profit, with an average return of +10.05% per trade.

2 Years

Vamil DivanGuggenheim

Success Rate

30/33 ratings generated profit

Average Return

+14.49%

Copying Vamil Divan's trades and holding each position for 2 Years would result in 90.91% of your transactions generating a profit, with an average return of +14.49% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1PFE Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 1PFE has received 16 Buy Ratings, 29 Hold Ratings, and 1 Sell Ratings. 1PFE average Analyst price target in the past 3 months is 26.52.

Each month's total comprises the sum of three months' worth of ratings.

1PFE Financial Forecast

1PFE Earnings Forecast

Next quarter’s earnings estimate for 1PFE is €0.65 with a range of €0.50 to €0.75. The previous quarter’s EPS was €0.69. 1PFE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 1PFE has Performed in-line its overall industry.

1PFE Sales Forecast

Next quarter’s sales forecast for 1PFE is €14.19B with a range of €13.11B to €15.04B. The previous quarter’s sales results were €13.42B. 1PFE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 1PFE has Performed in-line its overall industry.

1PFE Stock Forecast FAQ

What is IT:1PFE’s average 12-month price target, according to analysts?

Based on analyst ratings, Pfizer’s 12-month average price target is 26.52.

What is IT:1PFE’s upside potential, based on the analysts’ average price target?

Pfizer has 10.03% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Pfizer a Buy, Sell or Hold?

Pfizer has a consensus rating of Moderate Buy, which is based on 8 buy ratings, 14 hold ratings and 1 sell ratings.

What is Pfizer’s share price target?

The average share price target for Pfizer is 26.52. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €32.23 ,and the lowest forecast is €22.38. The average share price target represents 10.03% Increase from the current price of €24.1.

What do analysts say about Pfizer?

Pfizer’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 23 Wall Streets Analysts.

How can I buy shares of Pfizer?

To buy shares of IT:1PFE, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Pfizer (1PFE) Stock Forecast & Price Target

1PFE Analyst Ratings

1PFE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Pfizer

1PFE Analyst Recommendation Trends

1PFE Financial Forecast

1PFE Earnings Forecast

1PFE Sales Forecast

1PFE Stock Forecast FAQ

Detailed List of Analyst Forecasts